Moexipril (hydrochloride)

Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride) . Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects[1]-[4].

Product Specifications

CAS Number

[82586-52-5]

Product Name Alternative

RS-10085

UNSPSC

12352005

Hazard Statement

H400

Target

Angiotensin-converting Enzyme (ACE) ; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Moexipril-hydrochloride.html

Concentration

10mM

Purity

98.42

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O.Cl

Molecular Formula

C27H35ClN2O7

Molecular Weight

535.03

Precautions

H400

References & Citations

[1]Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44 (8) : p. 827-36.|[2]Edling, O., et al., Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther, 1995. 275 (2) : p. 854-63.|[3]Friehe H, et al. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb. 47 (2) :132-44.|[4]Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373 (1) :21-33.